{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:51:40Z","timestamp":1791427900638,"version":"4.3.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":120,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["GA N\u00b0 101095426"],"award-info":[{"award-number":["GA N\u00b0 101095426"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer\u2019s disease (AD) is a multifactorial neurodegenerative disorder characterized by amyloid-\u03b2 (A\u03b2) and tau pathology, neuroaxonal damage, and neuroinflammation. While blood biomarkers, such as tau, neurofilament light chain (NfL), and A\u03b2 isoforms, reflect AD pathology, the systemic metabolic alterations contributing to the disease remain poorly defined. This study aims to explore associations between plasma metabolites and key protein biomarkers linked to AD pathology in a large, population-based cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Plasma levels of A\u03b240, A\u03b242, total-tau (t-tau), and NfL were measured using the highly sensitive Simoa NF-light and N3PA assays (Quanterix platform) among over 3,000 participants from the Rotterdam Study. Plasma metabolites were quantified using the Nightingale NMR-based (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092,871) and Metabolon MS-based (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091,491) platforms. Multivariable linear regression models, adjusted for demographic, lifestyle, and genetic factors, were applied. Analyses were stratified by sex and APOE genotype. Sensitivity analyses excluded participants with dementia, stroke, or impaired kidney function.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Triglyceride-rich lipoproteins across VLDL, LDL, and HDL subclasses were positively associated with both A\u03b2 isoforms. Among them, Triglyceride-rich lipoproteins in small VLDL showed the strongest association with A\u03b240 (\u03b2\u2009=\u20090.168, FDR\u2009=\u20094.362e-16). Conversely, HDL cholesterol fractions showed inverse associations with A\u03b2. GlycA (\u03b2\u2009&gt;\u20090.097, FDR\u2009&lt;\u20092.092e-05) and creatinine (\u03b2\u2009&gt;\u20090.253, FDR &lt; 3.371e-24) were positively associated with all Alzheimer\u2019s disease biomarkers, while albumin was inversely related to tau (\u03b2 = -0.094, FDR\u2009=\u20091.924e-04) and NfL (\u03b2 = -0.079, FDR\u2009=\u20094.210e-05). On the Metabolon platform, S-adenosylhomocysteine (\u03b2\u2009&gt;\u20090.206, FDR\u2009&lt;\u20091.303e-09) was positively associated with all biomarkers, while uridine and 2\u2032-deoxyuridine showed inverse associations with A\u03b240, t-tau, and NfL. Stratified analyses indicated stronger GlycA-tau associations in APOE \u03b52 carriers and sex-specific effects for amino acids and ApoA1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings highlight metabolites involved in lipid transport, inflammation, amino acid metabolism, and methylation as being linked to AD-related protein biomarkers. These results provide novel insights into systemic metabolic pathways underlying AD and suggest that certain metabolites may serve as potential biomarkers for early detection and risk stratification in AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-026-02108-2","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:37:21Z","timestamp":1781048241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Associations of plasma metabolites with protein biomarkers linked to Alzheimer\u2019s disease pathology in the Rotterdam Study"],"prefix":"10.1186","volume":"18","author":[{"given":"Midas M.","family":"Kuilman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzad","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amos C.","family":"Pomp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Kaddurah-Daouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Arfan","family":"Ikram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Ghanbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"2108_CR1","doi-asserted-by":"crossref","unstructured":"Alzheimer's Association. Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2023;19(4):1598\u2013695.","DOI":"10.1002\/alz.13016"},{"issue":"4","key":"2108_CR2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","volume":"71","author":"GS Bloom","year":"2014","unstructured":"Bloom GS. Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71(4):505\u20138.","journal-title":"JAMA Neurol"},{"issue":"9","key":"2108_CR3","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.7150\/ijbs.57078","volume":"17","author":"H Zhang","year":"2021","unstructured":"Zhang H, et al. Interaction between Abeta and Tau in the Pathogenesis of Alzheimer\u2019s Disease. Int J Biol Sci. 2021;17(9):2181\u201392.","journal-title":"Int J Biol Sci"},{"issue":"4","key":"2108_CR4","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/brain\/awaa054","volume":"143","author":"F de Wolf","year":"2020","unstructured":"de Wolf F, et al. Plasma tau, neurofilament light chain and amyloid-beta levels and risk of dementia; a population-based cohort study. Brain. 2020;143(4):1220\u201332.","journal-title":"Brain"},{"issue":"2","key":"2108_CR5","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3233\/JAD-230932","volume":"96","author":"Y Dong","year":"2023","unstructured":"Dong Y, et al. Plasma Amyloid-beta, Total Tau, and Neurofilament Light Chain Across the Alzheimer\u2019s Disease Clinical Spectrum: A Population-Based Study. J Alzheimers Dis. 2023;96(2):845\u201358.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2108_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13195-025-01778-8","volume":"17","author":"M Kubota","year":"2025","unstructured":"Kubota M, et al. Plasma biomarkers for early detection of alzheimer\u2019s disease: a cross-sectional study in a Japanese cohort. Alzheimers Res Ther. 2025;17(1):131.","journal-title":"Alzheimers Res Ther"},{"key":"2108_CR7","doi-asserted-by":"crossref","unstructured":"Zou K, Abdullah M, Michikawa M. Current Biomarkers for Alzheimer\u2019s Disease: From CSF to Blood. J Pers Med. 2020;10(3):85.","DOI":"10.3390\/jpm10030085"},{"issue":"10","key":"2108_CR8","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1038\/s41380-020-0818-1","volume":"26","author":"MS Kang","year":"2021","unstructured":"Kang MS, et al. Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer\u2019s disease. Mol Psychiatry. 2021;26(10):5989\u20136001.","journal-title":"Mol Psychiatry"},{"key":"2108_CR9","doi-asserted-by":"publisher","first-page":"110848","DOI":"10.1016\/j.pnpbp.2023.110848","volume":"128","author":"M Amidfar","year":"2024","unstructured":"Amidfar M, Askari G, Kim YK. Association of metabolic dysfunction with cognitive decline and Alzheimer\u2019s disease: A review of metabolomic evidence. Prog Neuropsychopharmacol Biol Psychiatry. 2024;128:110848.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"10452","key":"2108_CR10","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","volume":"404","author":"G Livingston","year":"2024","unstructured":"Livingston G, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572\u2013628.","journal-title":"Lancet"},{"issue":"2","key":"2108_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10654-023-01094-1","volume":"39","author":"MA Ikram","year":"2024","unstructured":"Ikram MA, et al. The Rotterdam Study. Design update and major findings between 2020 and 2024. Eur J Epidemiol. 2024;39(2):183\u2013206.","journal-title":"Eur J Epidemiol"},{"key":"2108_CR12","doi-asserted-by":"crossref","unstructured":"Ahmad S, et al. The blood metabolome of cognitive function and brain health in middle-aged adults - influences of genes, gut microbiome, and exposome. medRxiv; 2024.","DOI":"10.1101\/2024.12.16.24317793"},{"key":"2108_CR13","doi-asserted-by":"crossref","unstructured":"Jayanti S et al. The Role of Bilirubin and the Other Yellow Players in Neurodegenerative Diseases. Antioxid (Basel). 2020;9(9):900.","DOI":"10.3390\/antiox9090900"},{"issue":"6","key":"2108_CR14","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s11011-025-01653-3","volume":"40","author":"RK Sidhu","year":"2025","unstructured":"Sidhu RK, Mittal Y, Aran KR. Bilirubin: a game-changer in alzheimer\u2019s therapy? Unveiling its neuroprotective and disease-modifying potential. Metab Brain Dis. 2025;40(6):224.","journal-title":"Metab Brain Dis"},{"issue":"2","key":"2108_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3233\/JAD-170485","volume":"60","author":"LM Giil","year":"2017","unstructured":"Giil LM, et al. Kynurenine Pathway Metabolites in Alzheimer\u2019s Disease. J Alzheimers Dis. 2017;60(2):495\u2013504.","journal-title":"J Alzheimers Dis"},{"key":"2108_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/978-1-4615-0135-0_19","volume":"527","author":"GJ Guillemin","year":"2003","unstructured":"Guillemin GJ, et al. Quinolinic acid in the pathogenesis of Alzheimer\u2019s disease. Adv Exp Med Biol. 2003;527:167\u201376.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"2108_CR17","doi-asserted-by":"publisher","first-page":"983","DOI":"10.3233\/JAD-181252","volume":"68","author":"S Lee","year":"2019","unstructured":"Lee S, et al. Low-Density Lipoprotein Particle Size Subfractions and Cerebral Amyloidosis. J Alzheimers Dis. 2019;68(3):983\u201390.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"2108_CR18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/alz.12649","volume":"19","author":"AE Martinez","year":"2023","unstructured":"Martinez AE, et al. The small HDL particle hypothesis of Alzheimer\u2019s disease. Alzheimers Dement. 2023;19(2):391\u2013404.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"2108_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1001\/jamaneurol.2013.5390","volume":"71","author":"B Reed","year":"2014","unstructured":"Reed B, et al. Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol. 2014;71(2):195\u2013200.","journal-title":"JAMA Neurol"},{"issue":"3","key":"2108_CR20","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1038\/emm.2015.3","volume":"47","author":"B Kim","year":"2015","unstructured":"Kim B, Feldman EL. Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Exp Mol Med. 2015;47(3):e149.","journal-title":"Exp Mol Med"},{"key":"2108_CR21","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.2147\/DDDT.S173970","volume":"12","author":"SK Rad","year":"2018","unstructured":"Rad SK, et al. Mechanism involved in insulin resistance via accumulation of beta-amyloid and neurofibrillary tangles: link between type 2 diabetes and Alzheimer\u2019s disease. Drug Des Devel Ther. 2018;12:3999\u20134021.","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"2108_CR22","first-page":"4104","volume":"130","author":"PJ Meakin","year":"2020","unstructured":"Meakin PJ, et al. Elevated circulating amyloid concentrations in obesity and diabetes promote vascular dysfunction. J Clin Invest. 2020;130(8):4104\u201317.","journal-title":"J Clin Invest"},{"issue":"1","key":"2108_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41392-021-00805-y","volume":"6","author":"Y Wang","year":"2021","unstructured":"Wang Y, et al. Natural killer cell-derived exosomal miR-1249-3p attenuates insulin resistance and inflammation in mouse models of type 2 diabetes. Signal Transduct Target Ther. 2021;6(1):409.","journal-title":"Signal Transduct Target Ther"},{"key":"2108_CR24","doi-asserted-by":"crossref","unstructured":"Sprenger KG et al. Lipid and Lipoprotein Metabolism in Microglia: Alzheimer\u2019s Disease Mechanisms and Interventions. J Lipid Res. 2025;66(10):100872.","DOI":"10.1016\/j.jlr.2025.100872"},{"issue":"9","key":"2108_CR25","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s11095-021-03098-6","volume":"38","author":"EM Rhea","year":"2021","unstructured":"Rhea EM, Banks WA. Interactions of Lipids, Lipoproteins, and Apolipoproteins with the Blood-Brain Barrier. Pharm Res. 2021;38(9):1469\u201375.","journal-title":"Pharm Res"},{"issue":"8","key":"2108_CR26","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.4103\/1673-5374.274328","volume":"15","author":"B Polis","year":"2020","unstructured":"Polis B, Samson AO. Role of the metabolism of branched-chain amino acids in the development of Alzheimer\u2019s disease and other metabolic disorders. Neural Regen Res. 2020;15(8):1460\u201370.","journal-title":"Neural Regen Res"},{"key":"2108_CR27","doi-asserted-by":"crossref","unstructured":"Siddik MAB et al. Branched-Chain Amino Acids Are Linked with Alzheimer\u2019s Disease-Related Pathology and Cognitive Deficits. Cells. 2022;11(21):3523.","DOI":"10.3390\/cells11213523"},{"issue":"1","key":"2108_CR28","doi-asserted-by":"publisher","first-page":"13604","DOI":"10.1038\/s41598-017-12931-1","volume":"7","author":"SC Larsson","year":"2017","unstructured":"Larsson SC, Markus HS. Branched-chain amino acids and Alzheimer\u2019s disease: a Mendelian randomization analysis. Sci Rep. 2017;7(1):13604.","journal-title":"Sci Rep"},{"issue":"16","key":"2108_CR29","doi-asserted-by":"publisher","first-page":"7358","DOI":"10.1021\/acs.jmedchem.8b01007","volume":"61","author":"HC Chien","year":"2018","unstructured":"Chien HC, et al. Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1). J Med Chem. 2018;61(16):7358\u201373.","journal-title":"J Med Chem"},{"issue":"6","key":"2108_CR30","doi-asserted-by":"publisher","first-page":"E1167","DOI":"10.1152\/ajpendo.00193.2003","volume":"285","author":"RL O\u2019Kane","year":"2003","unstructured":"O\u2019Kane RL, Hawkins RA. Na+-dependent transport of large neutral amino acids occurs at the abluminal membrane of the blood-brain barrier. Am J Physiol Endocrinol Metab. 2003;285(6):E1167\u201373.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"2108_CR31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13195-025-01692-z","volume":"17","author":"B Arslan","year":"2025","unstructured":"Arslan B, et al. The impact of kidney function on Alzheimer\u2019s disease blood biomarkers: implications for predicting amyloid-beta positivity. Alzheimers Res Ther. 2025;17(1):48.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2108_CR32","doi-asserted-by":"publisher","first-page":"17423","DOI":"10.1038\/s41598-024-67177-5","volume":"14","author":"N Liang","year":"2024","unstructured":"Liang N, et al. Peripheral inflammation is associated with brain atrophy and cognitive decline linked to mild cognitive impairment and Alzheimer\u2019s disease. Sci Rep. 2024;14(1):17423.","journal-title":"Sci Rep"},{"issue":"4","key":"2108_CR33","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00702-003-0096-5","volume":"111","author":"BP Kennedy","year":"2004","unstructured":"Kennedy BP, et al. Elevated S-adenosylhomocysteine in Alzheimer brain: influence on methyltransferases and cognitive function. J Neural Transm (Vienna). 2004;111(4):547\u201367.","journal-title":"J Neural Transm (Vienna)"},{"issue":"4","key":"2108_CR34","doi-asserted-by":"publisher","first-page":"246","DOI":"10.2174\/138920210791233090","volume":"11","author":"F Coppede","year":"2010","unstructured":"Coppede F. One-carbon metabolism and Alzheimer\u2019s disease: focus on epigenetics. Curr Genomics. 2010;11(4):246\u201360.","journal-title":"Curr Genomics"},{"issue":"4","key":"2108_CR35","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/ana.24135","volume":"75","author":"A Altmann","year":"2014","unstructured":"Altmann A, et al. Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol. 2014;75(4):563\u201373.","journal-title":"Ann Neurol"},{"issue":"13","key":"2108_CR36","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1212\/WNL.0000000000004425","volume":"89","author":"L Mosconi","year":"2017","unstructured":"Mosconi L, et al. Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging. Neurology. 2017;89(13):1382\u201390.","journal-title":"Neurology"},{"issue":"2","key":"2108_CR37","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1212\/WNL.0000000000009781","volume":"95","author":"A Rahman","year":"2020","unstructured":"Rahman A, et al. Sex-driven modifiers of Alzheimer risk: A multimodality brain imaging study. Neurology. 2020;95(2):e166\u201378.","journal-title":"Neurology"},{"issue":"10","key":"2108_CR38","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.tins.2008.07.003","volume":"31","author":"RD Brinton","year":"2008","unstructured":"Brinton RD. The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends Neurosci. 2008;31(10):529\u201337.","journal-title":"Trends Neurosci"},{"issue":"1","key":"2108_CR39","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41398-025-03625-8","volume":"15","author":"N Amin","year":"2025","unstructured":"Amin N, et al. Interplay between age, APOE E4 and the metabolome in plasma and brain in Alzheimer\u2019s disease. Transl Psychiatry. 2025;15(1):460.","journal-title":"Transl Psychiatry"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02108-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02108-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02108-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:35:51Z","timestamp":1791426951000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-02108-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2108"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02108-2","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Rotterdam Study has been approved under the Population Study Act by the Dutch Ministry of Health, Welfare and Sports, and written informed consent was obtained from all participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We confirm that the manuscript does not include any personally identifiable information or sensitive data, and we provide consent for its publication in\n                      Alz Res Ther\n                      .","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Kaddurah-Daouk is an inventor on a series of patents on use of metabolomics for the diagnosis and treatment of CNS diseases and holds equity in Metabolon Inc., Chymia, and Metabosensor. The other authors declare that they have no conflicts of interest to disclose.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"225"}}